media – Page 120 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Cambridge researchers use AI to accelerate drug design for Parkinson’s disease

The progressive neurological condition affects more than six million people worldwide Researchers from the University of Cambridge have designed and used an artificial-intelligence (AI)-based approach to advance drug design and accelerate the search for Parkinson’s disease (PD) treatments. Published in the journal Nature Chemical, researchers used AI to identify compounds that block the clumping or aggregation of alpha-synuclein, the key protein that characterises PD. Affecting more than six million people worldwide, PD is a progressive neurological condition that slowly deteriorates parts of the brain. As well as motor symptoms, PD can also affect the gastrointestinal system, nervous system, sleeping patterns, mood and cognition and can contribute to a reduced quality of life and significant disability. Researchers developed and used a machine learning technique to screen a chemical library that contained millions of entries to identify small molecules that bind to the amyloid aggregates and block their proliferation. The process of ...
- Source: drugdu
- 148
- May 6, 2024
Study finds mechanical changes in tumour tissue offer new insights for cancer research

Bladder cancer, including papillary tumours, is the ninth most common cancer type worldwide Researchers from ETH Zurich and University Hospital Basel have revealed new insights for cancer research when focusing on mechanical changes in tumour tissue after investigating the early stages of bladder cancer. Researchers aimed to understand what governs the direction in which bladder tumours grow and whether it plays a role in malignant and benign formations. Currently the ninth most common cancer type worldwide, bladder cancer occurs when cells in the bladder start to grow without control. Papillary tumours, long, slender benign or malignant tumours that grow from tissue that lines the inside of the organ, are usually easy to treat, while muscle-invasive bladder cancer, which spreads into the thick muscle of the bladder wall, requires surgical removal of the bladder. Similar to bronchioles in the lungs, researchers wondered whether molecular mechanisms could be responsible for creating the ...
- Source: drugdu
- 104
- May 6, 2024
Research Shows Generative AI In The EHR Can Work Well, But Only With Human Oversight

As the burden of documentation and various other administrative duties has increased, physician burnout has reached historical levels. In response, EHR vendors are embedding generative AI tools to aid physicians by drafting their responses to patient messages. However, there is a lot that we don’t yet know about these tools’ accuracy and effectiveness. Researchers at Mass General Brigham recently conducted research to learn more about how these generative AI solutions are performing. They published a study last week in The Lancet Digital Health showing that these AI tools can be effective at reducing physicians’ workloads and improving patient education — but also that these tools have limitations that require human oversight. For the study, the researchers used OpenAI’s GPT-4 large language model to produce 100 different hypothetical questions from patients with cancer. The researchers had GPT-4 answer these questions, as well as six radiation oncologists who responded manually. Then, the ...
- Source: drugdu
- 102
- May 6, 2024
Cue Health to cut 230 employees

Dive Brief Cue Health plans to cut 230 employees, or nearly half of its staff, as it looks to reduce costs amid declining COVID-19 test sales. The San Diego-based company grew quickly during the pandemic when it brought in government and private contracts for its point-of-care molecular tests. Now, Cue faces questions about its ability to continue as losses add up and revenue declines. The changes are intended to refocus Cue’s business on its Cue Health Monitoring System, including developing and deploying point-of-care tests, spokesperson Rachel Rudo wrote in an email. “In alignment with this strategy, Cue has significantly reduced, or removed altogether, functions that don’t directly support this strategy,” Rudo said. Dive Insight Cue has gone through several rounds of layoffs as the testing company looks to control costs. In January, the company cut more than 200 positions across two rounds of layoffs, and Cue also slashed hundreds of ...
- Source: drugdu
- 97
- May 6, 2024
Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds

Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1. By Frank Vinluan Amgen aims to challenge the Novo Nordisk and Eli Lilly duopoly in the market for injectable obesity medications, and the company is now preparing for Phase 3 testing of an injectable drug candidate that would introduce new competition. While executives are not yet sharing specific details of the clinical data that support these plans, Amgen’s drug candidate could have dosing and manufacturing advantages. The update for the drug, maridebart cafraglutide or MariTide (known in earlier stages of development as AMG 133), came with Amgen’s report of financial results for the first quarter of 2024. CEO Robert Bradway said the company ...
- Source: drugdu
- 111
- May 6, 2024
Novartis Set to Acquire Mariana Oncology to Enhance Radioligand Therapy Pipeline

Don Tracy, Associate Editor Deal includes a number of radioligand therapies targeting solid tumors, such as breast, prostate, and lung cancers. Novartis announced that it has acquired Mariana Oncology, a biotech specializing in developing radioligand therapies (RLTs) for cancer treatment. According to the company, the acquisition is expected to enhance Novartis’ existing RLT pipeline and add major research capabilities. These programs target breast, prostate, and lung cancers, and features a leading developmental candidate, MC-339, for small cell lung cancer. As per terms of the agreement, Novartis is expected to make an upfront payment of $1 billion, with further potential payments of up to $750 million upon the completion of pre-specified milestones.1 “The acquisition of Mariana Oncology reflects our commitment to radioligand therapy as one of our company’s key technology platforms and strengthens our leadership in this field,” said Fiona Marshall, president, biomedical research, Novartis, in a press release. “We are ...
- Source: drugdu
- 117
- May 6, 2024
【EXPERT Q&A】What is CAPA for Medical Devices?

Drugdu.com expert’s response: Corrective and Preventive Actions (CAPA) in medical devices refer to a series of measures taken in response to identified issues or defects. CAPA aims to ensure the safety and effectiveness of medical devices and compliance with regulatory requirements. These measures include: 1.Corrective Actions: Steps taken to address existing issues or defects, aimed at eliminating or correcting their root causes to prevent recurrence. This may involve repairs, improvements to product design, or enhancements to manufacturing processes. 2.Preventive Actions: Measures taken to address potential issues or defects, intended to prevent future quality problems. This may include improving product design, updating manufacturing processes, or enhancing training. CAPA is an essential component of the quality management system for medical devices, often detailed in standards such as ISO 13485. Implementing CAPA helps ensure the safety, effectiveness, and quality of medical devices, while also ensuring compliance with regulatory requirements.
- Source: drugdu
- 173
- May 6, 2024
Lupin Digital Health’s Lyfe Platform gets Class C Medical Device License from CDSCO

Lupin Digital Health’s Lyfe platform has received approval as a Class C Medical Device from the Central Drugs Standard Control Organisation (CDSCO). A press statement informed that Lyfe is now India’s first clinically proven remote cardiac rehabilitation program, designed to enhance heart health and quality of life. By providing tailored, accessible solutions in the comfort of patients’ homes, Lyfe empowers individuals to confidently manage their heart health. Rajeev Sibal, President – India Region Formulations, Lupin, stated, “This approval reaffirms our dedication to excellence in cardiac care. We are proud to be at the forefront of digital therapeutics in India, signifying our commitment to supporting cardiologists with patient-centric solutions and improving cardiovascular outcomes.” Elaborating on the significance of receiving this license, Sidharth Srinivasan, CEO, Lupin Digital Health added, “Securing the Class C Medical Device license for Lyfe is a significant achievement. It validates Lyfe as a best-in-class platform to support millions ...
- Source: drugdu
- 80
- May 5, 2024
BigHat Biosciences partners with Janssen Biotech

Strategic collaboration to leverage BigHat’s AI/ML (Artificial Intelligence / Machine Learning) guided Milliner platform to design high-quality next-generation protein therapeutics BigHat Biosciences, a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform announced a collaboration with Janssen Biotech Inc., a Johnson & Johnson company. This strategic collaboration combines the drug discovery, clinical development and data science expertise from Johnson & Johnson with BigHat’s Milliner platform, a suite of machine learning technologies integrated with a high-speed wet lab, to guide the design and selection for high-quality antibodies for multiple Neuroscience therapeutic targets. The agreement was facilitated by Johnson & Johnson Innovation. BigHat’s antibody design platform, Milliner, integrates a synthetic biology-based high-speed wet lab with machine learning technologies into a full-stack antibody discovery and engineering platform, to engineer antibodies with more complex functions and better biophysical properties. This approach reduces the difficulty of designing antibodies and other therapeutic proteins ...
- Source: drugdu
- 107
- May 5, 2024
Abbott Earns FDA Approval For Dissolving Stent That Unclogs Arteries Below The Knee

Abbott earned a groundbreaking FDA approval on Monday for its dissolving stent designed to unclog arteries below the knee. The device, called the Esprit BTK System, is meant to treat patients who have chronic limb-threatening ischemia below the knee. This condition is characterized by insufficient blood flow to the lower extremities, which leads to persistent pain, ulcers and tissue necrosis — with a significant risk of limb amputation if left untreated Chronic limb-threatening ischemia below the knee may be the most severe form of peripheral artery disease, said Jennifer Jones-McMeans, divisional vice president of global clinical affairs at Abbott’s vascular business. “This is really a landmark moment,” she said in an interview. “We’re looking at the first dissolving stent to treat below-the-knee arterial disease. And really, when you look at this severe form of upper artery disease, it’s considered kind of the terminal end of this disease — meaning that these patients have ...
- Source: drugdu
- 109
- May 5, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.